Catalent, Inc. (NYSE:CTLT) Shares Bought by UBS Group AG

UBS Group AG lifted its stake in shares of Catalent, Inc. (NYSE:CTLT - Free Report) by 2.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 726,563 shares of the company's stock after buying an additional 18,752 shares during the period. UBS Group AG owned approximately 0.40% of Catalent worth $32,644,000 at the end of the most recent quarter.

• S&P 500's surge to new highs: Bull trap hiding in plain sight?

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Tokio Marine Asset Management Co. Ltd. lifted its stake in shares of Catalent by 6.2% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company's stock worth $256,000 after buying an additional 331 shares during the period. Teacher Retirement System of Texas raised its holdings in shares of Catalent by 2.6% during the third quarter. Teacher Retirement System of Texas now owns 13,966 shares of the company's stock worth $636,000 after purchasing an additional 350 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Catalent by 0.7% during the fourth quarter. Arizona State Retirement System now owns 49,546 shares of the company's stock worth $2,226,000 after purchasing an additional 365 shares during the last quarter. Treasurer of the State of North Carolina raised its holdings in shares of Catalent by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 81,729 shares of the company's stock worth $3,721,000 after purchasing an additional 421 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in shares of Catalent by 2.3% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 18,907 shares of the company's stock worth $849,000 after purchasing an additional 434 shares during the last quarter.

Wall Street Analyst Weigh In

CTLT has been the subject of several recent research reports. UBS Group reissued a "neutral" rating and set a $63.50 target price (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. StockNews.com initiated coverage on shares of Catalent in a report on Tuesday, May 21st. They set a "sell" rating for the company. Stephens reissued an "equal weight" rating and set a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. Finally, Royal Bank of Canada reissued a "sector perform" rating and set a $63.50 target price on shares of Catalent in a report on Tuesday, February 20th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $53.14.

• Can financial, healthcare, energy stocks rise as rates stay high?

Read Our Latest Report on CTLT

Catalent Stock Up 0.3 %

CTLT stock opened at $54.82 on Monday. The stock has a market capitalization of $9.92 billion, a P/E ratio of -8.99, a P/E/G ratio of 5.88 and a beta of 1.18. The firm has a 50-day simple moving average of $56.02 and a 200-day simple moving average of $50.83. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. Catalent, Inc. has a 52 week low of $31.80 and a 52 week high of $60.20.

• Flee to Healthcare Stocks if Recession Rears its Head?

Catalent (NYSE:CTLT - Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.21 by ($0.36). The company had revenue of $1.07 billion for the quarter, compared to analysts' expectations of $1.11 billion. Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. Equities analysts forecast that Catalent, Inc. will post 0.31 earnings per share for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Further Reading

• Five stocks we like better than Catalent
• What is the FTSE 100 index?
• Norwegian Cruise Line Sets Sail on Record Bookings Raised EPS
• What is Put Option Volume?
• The Best EV Stock You Haven't Considered
• What Are the FAANG Stocks and Are They Good Investments?
• MarketBeat Week in Review – 5/20 - 5/24

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad)

Should you invest $1,000 in Catalent right now?

Before you consider Catalent, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalent wasn't on the list.

While Catalent currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here